We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
COVID isn’t going anywhere soon and any type of news regarding HEMO in this area and the share price will explode.
RNS Number : 8905P
Hemogenyx Pharmaceuticals PLC
15 June 2020
COVID-19 Project Update
Hemogenyx Pharmaceutical plc is pleased to announce progress in relation to its COVID-19 program.
On 24 June 2019, the Company announced the completion of the development of its second generation Advanced peripheral blood Hematopoietic Chimera ("ApbHC") or advanced humanised mice which offer several advantages over existing humanised mouse models. In particular, ApbHC do not develop Graft versus Host Disease ("GvHD"), which can compromise the utility of other similar types of humanised mice. The Directors considered that AbpHC, in addition to their use for disease modelling and drug testing, could potentially be used as a tool for the rapid discovery of human antibodies against human specific viral pathogens.
Subsequent work through the Company's subsidiary, Immugenyx, LLC ("Immugenyx"), had produced positive preliminary results prior to the emergence of COVID-19. In light of the emergence of the current major pandemic, work has been refocussed on COVID-19 with the aim of producing an effective treatment for those infected with the virus, and Immugenyx is currently taking the necessary steps to take this forward effectively. The work involves transplanting cells from blood samples from patients who have already recovered from COVID-19 into the ApbHC. This process will allow the Company's scientists to recreate a set of anti-SARS-CoV-2 virus antibodies which could be used for the treatment of COVID-19 sufferers.
In view of the continuing international spread of the disease and the propensity for coronaviruses to mutate and produce new strains, the Company's technology, in combination with the use of its humanised mice, should also form the basis for the treatment of future viral outbreaks.
Meanwhile, as announced on 22 April 2020, the Company has progressed its work, currently using blood samples from convalescent patients, to attempt to establish why some individuals who are infected with SARS-CoV-2 are asymptomatic, some exhibit mild symptoms, and some become very sick. This work will be of value in developing new forms of treatment, and especially in managing infection risk and assisting individuals better to establish their real risk of getting sick.
The additional funds raised recently have enabled the Company to take these and other developments forward significantly and at a faster pace.
At the same time, the Directors are aware of shareholder interest in the collaboration with Orgenesis Inc. ("Orgenesis"). The Board reminds shareholders of the collaboration agreement entered into by Immugenyx and Orgenesis in 2018, the principal terms of which are set out in the Company's announcement of 19 October 2018, and under which Orgenesis obtained the right to use and distribute the Company's Advanced Humanised Mice.
Hi Bowie, sounds like we have a bet then. I'll stick to my end.
You did say 'buy' at below 9p, so if someone wants to go offloading below 9p that's not my concern.
Anyway, whichever way the bet goes, I wish you well.
I think 9 is the base as vlad has buy options at 9 its going to get very exciting over next 6 weeks lunus keep up the good posting
Every man and his dog will be over the shares that have actual tests tommorow which I am already in....I will further the bet that you will not last the week out......
Hi Billy in all fairness to sell any large amount last thing Friday the price was under 9p so technically your shares were worth less then 9p less than 9 is 8.something so technically I was right....but ye go on then I'm in.....
Hi Bowie, how about a little bet?.....if you get a buy below 9p tomorrow I'll have a week off from posting and if you don't, you have a week off?.
I will be buying bk in tommorow when it 8.something p to buy :)
Yep, agreed Lunus, I don't think 40-50p is unrealistic on both realisations. Lets hope you're right. I even think both should happen this year
Lunus,
Equally, I'm a small time private investor and not ramping or deramping
I see this very much the same as you.
Openthebox he is not worth responding to he if sht could bounce he would not come down. And nothing wrong with being on council estate whats that got to do with anything . Why he comes on here i will never know. Few of you post good stuff
Oh holier than thou swimming.. you must be a barrel of laughs
Shaggy, good post, yeah all good with this share, ok one month later than planned to fit the i’s and cross the T’s but will be worth it, next month should see us around 15/16p waiting fir the news to drop, then it’s on to mid/high 20’s. Have a good weekend.
By the way the way 31st Dec is only 1 month added to the agreed timeframe
Swimming as usual normal, down beat deramp the share from you. It was 2nd Sept with 3 months on top of that for licence decision. We were in the licence decision period and that why the extension was provided. Lucas contact with Hemo have provided the question about would it be 3 months on from the 31st Dec. Which we now know is NO. The 2nd of Sept was never a end date as you think it was!
Swimminginoil why are you here?
Similarly why are you on many other boards running those shares down.
Go out and get laid or whatever is required to cheer you up.
4 month? Dec 31st is not 4 months dont call me,an idiot you wouldnt say it to my face would you
Read them urself then cine back on here